Manfred Ogris

Prof. Dr. Manfred Ogris

Department of Pharmaceutical Chemistry, Laboratory of MacroMolecular Cancer Therapeutics (MMCT), University of Vienna, 1010 Vienna, Austria
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 October 1998 in Gene Therapy
Verified
Journal Article
Closed access
MOManfred Ogris
Manfred Ogris
PSP Steinlein
P Steinlein
MKM Kursa
M Kursa
KMKarl Mechtler
Karl Mechtler
Ralf KircheisRalf Kircheis
Ralf Kircheis
Ernst WagnerErnst Wagner
Ernst Wagner

1 March 1998 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
WZWolfgang Zauner
Wolfgang Zauner
MOManfred Ogris
Manfred Ogris
Ernst WagnerErnst Wagner
Ernst Wagner

5 May 2004 in The Journal of Gene Medicine
Verified
Journal Article
Closed access
PDF file
SBSabine Boeckle
Sabine Boeckle
KGKatharina von Gersdorff
Katharina von Gersdorff
SPSilke van der Piepen
Silke van der Piepen
Carsten CulmseeCarsten Culmsee
Carsten Culmsee
Ernst WagnerErnst Wagner
Ernst Wagner
MOManfred Ogris
Manfred Ogris

1 May 1997 in Gene Therapy
Verified
Journal Article
Closed access
Ralf KircheisRalf Kircheis
Ralf Kircheis
Antoine KichlerAntoine Kichler
Antoine Kichler
GWG Wallner
G Wallner
MKM Kursa
M Kursa
MOManfred Ogris
Manfred Ogris
Ernst WagnerErnst Wagner
Ernst Wagner

1 March 2005 in Molecular Therapy
Verified
Journal Article
Open access
GWGreg F. Walker
Greg F. Walker
CFCarolin Fella
Carolin Fella
JPJaroslav Pelisek
Jaroslav Pelisek
JFJulia Fahrmeir
Julia Fahrmeir
SBSabine Boeckle
Sabine Boeckle
Ernst WagnerErnst Wagner
Ernst Wagner
Nonviral vectors should undergo "virus-like" changes compatible with the steps of gene delivery. Poly(ethylene) glycol (PEG) shielding of DNA/polycation polyplexes protects from nonspecific interactions with the extracellular environment. pH-triggered removal of the shield within the endosome may be advantageous. Polycation and PEG were linked via acylhydrazides or pyridylhydrazines. The pyridylhydrazone prepared from polylysine and propionaldehyde-PEG showed the greatest acid-dependent hydrolysis; at pH 5, 37 degrees C for 10 min, 90% hydrolyzed, while at pH 7.4 the half-life was 1.5 h. Particle size and zeta potential measurements of the polyplexes showed complete deshielding within 1 h at pH 5, while at pH 7.4 the shield remained at 4 h, 37 degrees C. For gene transfection a targeting conjugate was also included in the polyplex, transferrin as ligand for K562 and Neuro2A cells and epidermal growth factor for HUH-7 and Renca-EGFR cells. Marker gene expression showed that the reversibly shielded polyplexes exhibited up to 2 log orders of magnitude higher gene expression in vitro and 1 log magnitude higher gene expression in an in vivo mouse model, compared to the stably shielded control polyplexes. Engineering of polyplexes with more dynamic domains is an encouraging new direction in nonviral vector design.